Posted by Michael Wonder on 07 Apr 2026
NextCure receives fast track designation for SIM0505 (CDH6 ADC) in ovarian cancer
7 April 2026 - NextCure today announced that the US FDA has granted fast track designation for SIM0505 for the treatment of platinum-resistant ovarian cancer.
SIM0505 is an investigational antibody drug conjugate comprised of an antibody that targets cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor payload.
